Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Peter Nygren

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Anatomy

Chemicals & Drugs

Procedures

Physiology

Disorders

Concepts & Ideas

Drug Dose-Response Relationship

Phenomena

Drug Synergism

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
87
Larsson, Rolf
16
Kristensen, Jörgen
16
Fridborg, H
15
Dhar, Sumeer
15
Bergh, Jonas
15
Nilsson, Kenneth
14
Glimelius, Bengt
13
Gullbo, Joachim
10
Lindhagen, Elin
9
Lövborg, Henrik
9
Rickardson, Linda
8
Sundström, Christer
8
Liminga, G
7
Karlsson, Mats
7
Aleskog, Anna

Sign-in to see all Coauthors

Publications

TOP 3
Laryea Daniel; Isaksson Anders; Wright Colin W; Larsson Rolf; Nygren Peter
Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients.
Hansson J; Graf W; Påhlman L; Nygren P; Mahteme H
Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy.
Wiberg Kristina; Carlson Kristina; Aleskog Anna; Larsson Rolf; Nygren Peter; Lindhagen Elin
In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Peter Nygren (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Laryea Daniel; Isaksson Anders; Wright Colin W; Larsson Rolf; Nygren Peter
Characterization of the cytotoxic activity of the indoloquinoline alkaloid cryptolepine in human tumour cell lines and primary cultures of tumour cells from patients.
Investigational new drugs 2009;27(5):402-11.
2009: Hansson J; Graf W; Påhlman L; Nygren P; Mahteme H
Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2009;35(2):202-8.
2009: Wiberg Kristina; Carlson Kristina; Aleskog Anna; Larsson Rolf; Nygren Peter; Lindhagen Elin
In vitro activity of bortezomib in cultures of patient tumour cells--potential utility in haematological malignancies.
Medical oncology (Northwood, London, England) 2009;26(2):193-201.
2008: Aleskog Anna; Norberg Maria; Nygren Peter; Rickardson Linda; Kanduri Meena; Tobin Gerard; Aberg Magnus; Gustafsson Mats G; Rosenquist Richard; Lindhagen Elin
Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination.
Leukemia & lymphoma 2008;49(12):2333-43.
2008: Nygren Peter; Sandman Lars
[If you are young you get it, but if you are old you are left out. The significance of age for choice of treatment and priorities in cancer care]
Läkartidningen 2008;105(47):3417-9.
2008: Lindhagen Elin; Eriksson Anna; Wickström Malin; Danielsson Katarina; Grundmark Birgitta; Henriksson Roger; Nygren Peter; Aleskog Anna; Larsson Rolf; Höglund Martin
Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia.
European journal of haematology 2008;81(5):344-53.
2008: Wickström Malin; Haglund Caroline; Lindman Henrik; Nygren Peter; Larsson Rolf; Gullbo Joachim
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.
Investigational new drugs 2008;26(3):195-204.
2008: Lindhagen Elin; Nygren Peter; Larsson Rolf
The fluorometric microculture cytotoxicity assay.
Nature protocols 2008;3(8):1364-9.
2008: Nygren Peter; Blomqvist Lennart; Bergh Jonas; Aström Gunnar
Radiological assessment of tumour response to anti-cancer drugs: time to reappraise.
Acta oncologica (Stockholm, Sweden) 2008;47(2):316-8.
2007: Quartino Angelica; Karlsson Mats O; Freijs Agneta; Jonsson Niclas; Nygren Peter; Kristensen Jörgen; Lindhagen Elin; Larsson Rolf
Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia.
Journal of clinical pharmacology 2007;47(8):1014-21.
2007: Lindhagen Elin; Rickardson Linda; Elliott Gary; Leoni Lorenzo; Nygren Peter; Larsson Rolf; Aleskog Anna
Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro.
Investigational new drugs 2007;25(4):297-303.
2007: Fryknäs Mårten; Dhar Sumeer; Oberg Fredrik; Rickardson Linda; Rydåker Maria; Göransson Hanna; Gustafsson Mats; Pettersson Ulf; Nygren Peter; Larsson Rolf; Isaksson Anders
STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines.
International journal of cancer. Journal international du cancer 2007;120(1):189-95.
2007: Wickström Malin; Danielsson Katarina; Rickardson Linda; Gullbo Joachim; Nygren Peter; Isaksson Anders; Larsson Rolf; Lövborg Henrik
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients.
Biochemical pharmacology 2007;73(1):25-33.
2007: Lindman Henrik; Aström Gunnar; Ahlgren Johan; Villman Kenneth; Blomqvist Carl; Nygren Peter; Bergh Jonas
Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer.
Acta oncologica (Stockholm, Sweden) 2007;46(2):165-71.
2006: Rickardson Linda; Fryknäs Mårten; Haglund Caroline; Lövborg Henrik; Nygren Peter; Gustafsson Mats G; Isaksson Anders; Larsson Rolf
Screening of an annotated compound library for drug activity in a resistant myeloma cell line.
Cancer chemotherapy and pharmacology 2006;58(6):749-58.
2006: Fryknäs Mårten; Rickardson Linda; Wickström Malin; Dhar Sumeer; Lövborg Henrik; Gullbo Joachim; Nygren Peter; Gustafsson Mats G; Isaksson Anders; Larsson Rolf
Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening 2006;11(5):457-68.
2006: Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson M O
Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Cancer chemotherapy and pharmacology 2006;58(2):143-56.
2006: Dreilich Martin; Lindkvist Anna; Dhar Sumeer; Paulsson-Karlsson Ylva; Brattström Daniel; Nygren Peter; Rickardson Linda; Wagenius Gunnar; Bergqvist Michael
Telomerase activity is not a key determinant of sensitivity to standard cytotoxic drugs in human esophageal carcinoma cell lines.
Anti-cancer drugs 2006;17(5):503-9.
2006: Hedström Mariann; Kreuger Anders; Ljungman Gustaf; Nygren Peter; von Essen Louise
Accuracy of assessment of distress, anxiety, and depression by physicians and nurses in adolescents recently diagnosed with cancer.
Pediatric blood & cancer 2006;46(7):773-9.
2006: Lövborg Henrik; Oberg Fredrik; Rickardson Linda; Gullbo Joachim; Nygren Peter; Larsson Rolf
Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram.
International journal of cancer. Journal international du cancer 2006;118(6):1577-80.
2005: Rickardson L; Fryknäs M; Dhar S; Lövborg H; Gullbo J; Rydåker M; Nygren P; Gustafsson M G; Larsson R; Isaksson A
Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles.
British journal of cancer 2005;93(4):483-92.
2005: Villman Kenneth; Blomqvist Carl; Larsson Rolf; Nygren Peter
Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.
Anti-cancer drugs 2005;16(6):609-15.
2005: Nygren Peter; Hande Kenneth; Petty Kevin J; Fedgchin Margaret; van Dyck Kristien; Majumdar Anup; Panebianco Debbie; de Smet Marina; Ahmed Tuli; Murphy M Gail; Gottesdiener Keith M; Cocquyt Veronique; van Belle Simon
Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Cancer chemotherapy and pharmacology 2005;55(6):609-16.
2005: Aleskog Anna; Larsson Rolf; Höglund Martin; Kristensen Jörgen; Nygren Peter; Lindhagen Elin
In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia.
Anti-cancer drugs 2005;16(3):277-83.
2005: Persson Christina; Glimelius Bengt; Rönnelid Johan; Nygren Peter
Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study.
Nutrition (Burbank, Los Angeles County, Calif.) 2005;21(2):170-8.
2005: Sandström M; Lindman H; Nygren P; Lidbrink E; Bergh J; Karlsson M O
Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):413-21.
2005: Nygren Peter; Sørbye Halfdan; Osterlund Pia; Pfeiffer Per
Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.
Acta oncologica (Stockholm, Sweden) 2005;44(3):203-17.
2004: Aleskog Anna; Tobin Gerard; Laurell Anna; Thunberg Ulf; Lindhagen Elin; Roos Göran; Nilsson Kenneth; Nygren Peter; Sundström Christer; Höglund Martin; Larsson Rolf; Rosenquist Richard
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
European journal of haematology 2004;73(6):407-11.
2004: Gullbo Joachim; Lindhagen Elin; Bashir-Hassan Saadia; Tullberg Marcus; Ehrsson Hans; Lewensohn Rolf; Nygren Peter; De La Torre Manuel; Luthman Kristina; Larsson Rolf
Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.
Investigational new drugs 2004;22(4):411-20.
2004: Lövborg Henrik; Nygren Peter; Larsson Rolf
Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828.
Molecular cancer therapeutics 2004;3(5):521-6.
2004: Hovstadius Peter; Lindhagen Elin; Hassan Sadia; Nilsson Kenneth; Jernberg-Wiklund Helena; Nygren Peter; Binderup Lise; Larsson Rolf
Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines.
Anti-cancer drugs 2004;15(1):63-70.
2004: Gullbo Joachim; Lövborg Henrik; Dhar Sumeer; Lukinius Agneta; Oberg Fredrik; Nilsson Kenneth; Björkling Fredrik; Binderup Lise; Nygren Peter; Larsson Rolf
Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828.
Anti-cancer drugs 2004;15(1):45-54.
2004: Mahteme H; Hansson J; Berglund A; Påhlman L; Glimelius B; Nygren P; Graf W
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.
British journal of cancer 2004;90(2):403-7.
2003: Gullbo Joachim; Wallinder Charlotta; Tullberg Marcus; Lövborg Henrik; Ehrsson Hans; Lewensohn Rolf; Nygren Peter; Luthman Kristina; Larsson Rolf
Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.
Molecular cancer therapeutics 2003;2(12):1331-9.
2003: Sarapa Nenad; Britto Margaret R; Speed William; Jannuzzo MariaGabriella; Breda Massimo; James Christopher A; Porro MariaGrazia; Rocchetti Maurizio; Wanders Alkvin; Mahteme Haile; Nygren Peter
Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma.
Cancer chemotherapy and pharmacology 2003;52(5):424-30.
2003: Gullbo Joachim; Dhar Sumeer; Luthman Kristina; Ehrsson Hans; Lewensohn Rolf; Nygren Peter; Larsson Rolf
Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.
Anti-cancer drugs 2003;14(8):617-24.
2003: Gullbo Joachim; Wickström Malin; Tullberg Marcus; Ehrsson Hans; Lewensohn Rolf; Nygren Peter; Luthman Kristina; Larsson Rolf
Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.
Journal of drug targeting 2003;11(6):355-63.
2003: Henningsson A; Sparreboom A; Sandström M; Freijs A; Larsson R; Bergh J; Nygren P; Karlsson M O
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1105-14.
2003: Nygren P; Larsson R
Overview of the clinical efficacy of investigational anticancer drugs.
Journal of internal medicine 2003;253(1):46-75.
2003: Gullbo Joachim; Tullberg Marcus; Våbenø Jon; Ehrsson Hans; Lewensohn Rolf; Nygren Peter; Larsson Rolf; Luthman Kristina
Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.
Oncology research 2003;14(3):113-32.
2002: Martinsson P; Ekelund S; Nygren P; Larsson R
The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro--from cytotoxic synergy to complete inhibition of apoptosis.
British journal of pharmacology 2002;137(4):568-73.
2002: Ekelund Sara; Persson Ingrid; Larsson Rolf; Nygren Peter
Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patients.
Chemotherapy 2002;48(4):196-204.
2002: Ekelund Sara; Larsson Rolf; Nygren Peter
Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cells.
Anticancer research 2002;22(4):2269-74.
2002: Aleskog Anna; Jonsson Elin; Larsson Rolf; Nygren Peter; Kristensen Jörgen; Sundström Christer; Höglund Martin
In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low-grade non-Hodgkin's lymphoma.
British journal of haematology 2002;117(3):563-8.
2002: Lövborg Henrik; Martinsson Petra; Gullbo Joachim; Ekelund Sara; Nygren Peter; Larsson Rolf
Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells.
Biochemical pharmacology 2002;63(8):1491-8.
2002: Berglund Ake; Glimelius Bengt; Bergh Jonas; Brodin Ola; Fjällskog Marie-Louise; Hagberg Hans; von Heideman Anne; Larsson Rolf; Tholander Bengt; de la Torre Manuel; Aström Gunnar; Oberg Kjell; Parö Gunnar; Nygren Peter
Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial.
Medical oncology (Northwood, London, England) 2002;19(3):151-9.
2001: Martinsson P; Liminga G; Nygren P; Larsson R
Characteristics of etoposide-induced apoptotic cell death in the U-937 human lymphoma cell line.
Anti-cancer drugs 2001;12(8):699-705.
2001: Ekelund S; Nygren P; Larsson R
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.
Biochemical pharmacology 2001;61(10):1183-93.
2001: Glimelius B; Nygren P; Lamnevik G
[Cytostatic therapy in cancer--a SBU report]
Läkartidningen 2001;98(16):1905-10.
2001: Ekelund S; Sjöholm A; Nygren P; Binderup L; Larsson R
Cellular pharmacodynamics of the cytotoxic guanidino-containing drug CHS 828. Comparison with methylglyoxal-bis(guanylhydrazone).
European journal of pharmacology 2001;418(1-2):39-45.
2001: Martinsson P; de la Torre M; Binderup L; Nygren P; Larsson R
Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells.
European journal of pharmacology 2001;417(3):181-7.
2001: Hassan S B; de la Torre M; Nygren P; Karlsson M O; Larsson R; Jonsson E
A hollow fiber model for in vitro studies of cytotoxic compounds: activity of the cyanoguanidine CHS 828.
Anti-cancer drugs 2001;12(1):33-42.
2001: Jonsson E; Friberg L E; Karlsson M O; Hassan S B; Nygren P; Kristensen J; Tholander B; Binderup L; Larsson R
In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients.
Cancer letters 2001;162(2):193-200.
2001: Ragnhammar P; Brorsson B; Nygren P; Glimelius B;
A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence.
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):391-411.
2001: Permert J; Hafström L; Nygren P; Glimelius B;
A systematic overview of chemotherapy effects in pancreatic cancer.
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):361-70.
2001: Janunger K G; Hafström L; Nygren P; Glimelius B;
A systematic overview of chemotherapy effects in gastric cancer.
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):309-26.
2001: Ragnhammar P; Hafström L; Nygren P; Glimelius B;
A systematic overview of chemotherapy effects in colorectal cancer.
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):282-308.
2001: Nygren P;
What is cancer chemotherapy?
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):166-74.
2001: Nygren P; Glimelius B;
The Swedish Council on Technology Assessment in Health Care (SBU) report on Cancer Chemotherapy--Project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation.
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):155-65.
2001: Glimelius B; Bergh J; Brandt L; Brorsson B; Gunnars B; Hafström L; Haglund U; Högberg T; Janunger K G; Jönsson P E; Karlsson G; Kimby E; Lamnevik G; Nilsson S; Permert J; Ragnhammar P; Sörenson S; Nygren P
The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.
Acta oncologica (Stockholm, Sweden) 2001;40(2-3):135-54.
2000: Liminga G; Martinsson P; Jonsson B; Nygren P; Larsson R
Apoptosis induced by calcein acetoxymethyl ester in the human histiocytic lymphoma cell line U-937 GTB.
Biochemical pharmacology 2000;60(12):1751-9.
2000: von Heideman A; Sandström M; Csoka K; Tholander B; Larsson R; Bergh J; Nygren P
Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(10):1301-7.
2000: Jonsson E; Dhar S; Jonsson B; Nygren P; Graf W; Larsson R
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
European journal of cancer (Oxford, England : 1990) 2000;36(16):2120-7.
2000: Dhar S; Gullbo J; Csoka K; Eriksson E; Nilsson K; Nickel P; Larsson R; Nygren P
Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients.
European journal of cancer (Oxford, England : 1990) 2000;36(6):803-9.
1999: Liminga G; Jonsson B; Nygren P; Larsson R
On the mechanism underlying calcein-induced cytotoxicity.
European journal of pharmacology 1999;383(3):321-9.
1999: Karlsson M O; Molnar V; Freijs A; Nygren P; Bergh J; Larsson R
Pharmacokinetic models for the saturable distribution of paclitaxel.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(10):1220-3.
1999: Fridborg H; Jonsson E; Nygren P; Larsson R
Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic.
European journal of cancer (Oxford, England : 1990) 1999;35(3):424-32.
1998: Jonsson E; Fridborg H; Nygren P; Larsson R
Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients.
European journal of clinical pharmacology 1998;54(7):509-14.
1998: Larsson R; Dhar S; Ehrsson H; Nygren P; Lewensohn R
Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.
British journal of cancer 1998;78(3):328-35.
1998: Ekelund S; Nygren P; Larsson R
Microphysiometry: new technology for evaluation of anticancer drug activity in human tumor cells in vitro.
Anti-cancer drugs 1998;9(6):531-8.
1998: Dhar S; Nygren P; Liminga G; Sundström C; de la Torre M; Nilsson K; Larsson R
Relationship between cytotoxic drug response patterns and activity of drug efflux transporters mediating multidrug resistance.
European journal of pharmacology 1998;346(2-3):315-22.
1997: Csóka K; Tholander B; Gerdin E; de la Torre M; Larsson R; Nygren P
In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).
International journal of cancer. Journal international du cancer 1997;72(6):1008-12.
1997: Csóka K; Dhar S; Fridborg H; Larsson R; Nygren P
Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro.
Cancer 1997;79(6):1225-33.
1997: Jonsson E; Fridborg H; Csóka K; Dhar S; Sundström C; Nygren P; Larsson R
Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
British journal of cancer 1997;76(2):211-9.
1997: Martinsson P; Nygren P; Fridborg H; Nilsson K; Kristensen J; Larsson R
Cytotoxic activity of cyclosporin A and [3-keto-Bmt1]-[Val2]-cyclosporin (SDZ PSC 833) on tumour cells from patients with haematological malignancies.
European journal of clinical pharmacology 1997;52(3):199-203.
1996: Fridborg H; Nygren P; Dhar S; Csoka K; Kristensen J; Larsson R
In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells.
Journal of experimental therapeutics & oncology 1996;1(5):286-95.
1996: Dhar S; Nygren P; Csoka K; Botling J; Nilsson K; Larsson R
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.
British journal of cancer 1996;74(6):888-96.
1996: Ridefelt P; Larsson R; Nygren P; Larsson E; Nilsson K
Modulation of calcium signalling and proliferation in monoblastoid U-937 cells.
Anticancer research 1996;16(4A):1643-50.
1996: Jonsson B; Liminga G; Csoka K; Fridborg H; Dhar S; Nygren P; Larsson R
Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours.
European journal of cancer (Oxford, England : 1990) 1996;32A(5):883-7.
1995: Csoka K; Nygren P; Graf W; Påhlman L; Glimelius B; Larsson R
Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients.
International journal of cancer. Journal international du cancer 1995;63(3):356-60.
1995: Liminga G; Nygren P; Dhar S; Nilsson K; Larsson R
Cytotoxic effect of calcein acetoxymethyl ester on human tumor cell lines: drug delivery by intracellular trapping.
Anti-cancer drugs 1995;6(4):578-85.
1995: Csoka K; Liliemark J; Larsson R; Nygren P
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Seminars in oncology 1995;22(4 Suppl 11):47-53.
1995: Nygren P; Csoka K; Jonsson B; Fridborg H; Bergh J; Hagberg H; Glimelius B; Brodin O; Tholander B; Kreuger A
The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.
British journal of cancer 1995;71(3):478-81.
1995: Fridborg H; Nygren P; Larsson R
Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs.
Anti-cancer drugs 1995;6(1):64-9.
1994: Larsson R; Nygren P
Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors.
Cancer 1994;74(10):2857-62.
1994: Kristensen J; Nygren P; Liliemark J; Fridborg H; Killander A; Simonsson B; Oberg G; Larsson R
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(10):1712-7.
1994: Holmberg M; Sandberg C; Nygren P; Larsson R
Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein.
Anti-cancer drugs 1994;5(5):598-600.
1994: Csoka K; Larsson R; Tholander B; Gerdin E; de la Torre M; Nygren P
Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).
Gynecologic oncology 1994;54(2):163-70.
1994: Fridborg H; Jonsson B; Nygren P; Csoka K; Nilsson K; Oberg G; Kristensen J; Bergh J; Tholander B; Olsen L
Activity of cyclosporins as resistance modifiers in primary cultures of human haematological and solid tumours.
British journal of cancer 1994;70(1):11-7.
1994: Botling J; Liminga G; Larsson R; Nygren P; Nilsson K
Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein.
International journal of cancer. Journal international du cancer 1994;58(2):269-74.
1994: Liminga G; Nygren P; Larsson R
Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833.
Experimental cell research 1994;212(2):291-6.
1994: Fridborg H; Larsson R; Juhlin C; Rastad J; Akerström G; Backlin K; Nygren P
P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells.
Anticancer research 1994;14(3A):1009-16.
1994: Nygren P; Fridborg H; Csoka K; Sundström C; de la Torre M; Kristensen J; Bergh J; Hagberg H; Glimelius B; Rastad J
Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients.
International journal of cancer. Journal international du cancer 1994;56(5):715-20.
1994: Nygren P; Hagberg H; Glimelius B; Sundström C; Kristensen J; Christiansen I; Larsson R
In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric microculture cytotoxicity assay.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 1():127-31.
1994: Larsson R; Fridborg H; Liliemark J; Csoka K; Kristensen J; de la Torre M; Nygren P
In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours.
European journal of cancer (Oxford, England : 1990) 1994;30A(7):1022-6.
1993: Larsson R; Nygren P
Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model.
Anticancer research 1993;13(5C):1825-9.
1993: Larsson R; Fridborg H; Kristensen J; Sundström C; Nygren P
In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA).
British journal of cancer 1993;67(5):969-74.
1993: Larsson R; Nygren P
Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exemplified by acute leukaemia.
European journal of cancer (Oxford, England : 1990) 1993;29A(8):1208-12.
1992: Larsson R; Jonsson B; Csoka K; Kristensen J; Nilsson K; Nygren P
Selective cytotoxic activity of cyclosporins against tumor cells from patients with B cell chronic lymphocytic leukemia.
European journal of pharmacology 1992;228(4):237-40.
1992: Jonsson B; Nilsson K; Nygren P; Larsson R
SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Anti-cancer drugs 1992;3(6):641-6.
1992: Nygren P; Kristensen J; Jonsson B; Sundström C; Lönnerholm G; Kreuger A; Larsson R
Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(11):1121-8.
1992: Larssson R; Fridborg H; Csoka K; Bergh J; Nygren P
Cytotoxic action of cyclosporins on human tumor cell lines is not dependent on immunosuppressive activity.
Anticancer research 1992;12(5):1581-5.
1992: Larsson R; Kristensen J; Sandberg C; Nygren P
Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA).
International journal of cancer. Journal international du cancer 1992;50(2):177-85.
1992: Kristensen J; Jonsson B; Sundström C; Nygren P; Larsson R
In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia.
Medical oncology and tumor pharmacotherapy 1992;9(2):65-74.
1991: Nygren P; Larsson R; Gruber A; Peterson C; Bergh J
Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression.
British journal of cancer 1991;64(6):1011-8.
1991: Nygren P; Larsson R
Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators.
International journal of cancer. Journal international du cancer 1991;48(4):598-604.
1991: Larsson R; Bergh J; Nygren P
Combination of cyclosporin A and buthionine sulfoximine (BSO) as a pharmacological strategy for circumvention of multidrug resistance in small cell lung cancer cell lines selected for resistance to doxorubicin.
Anticancer research 1991;11(1):455-9.
1990: Larsson R; Nygren P
Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in the human medullary thyroid carcinoma TT cell line not expressing the 170 kDa P-glycoprotein.
Cancer letters 1990;54(3):125-31.
1990: Larsson R; Nygren P; Ekberg M; Slater L
Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(8):567-71.
1990: Larsson R; Nygren P
Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells.
International journal of cancer. Journal international du cancer 1990;46(1):67-72.
1989: Larsson R; Nygren P
A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture.
Anticancer research 1989;9(4):1111-9.
1989: Larsson R; Nygren P; Forsbeck K; Gylfe E; Nilsson K
Early ionic events associated with phorbol ester induced differentiation and inhibition of cell growth in hematopoietic tumor cell lines.
Anticancer research 1989;9(1):1-7.
1988: Forsbeck K; Nilsson K; Nygren P; Larsson R; Gylfe E; Skoglund G; Ingelman-Sundberg M
Phorbol-ester-induced stable changes in the regulation of DNA synthesis and intracellular pH are accompanied by altered expression of protein kinase C in the monoblastoid cell line U-937.
International journal of cancer. Journal international du cancer 1988;42(2):284-8.
1988: Forsbeck K; Nygren P; Larsson R; Nilsson M; Nilsson K; Gylfe E
Cytoplasmic pH is differently regulated in the monoblastic U-937 and erythroleukemic K-562 cell lines.
Experimental cell research 1988;176(1):96-106.
1987: Nygren P; Larsson R; Forsbeck K; Nilsson K; Gylfe E
TPA induces cytoplasmic alkalinization in human monoblastic U-937 cells without activation of Na+/H+ exchange.
Experimental cell research 1987;171(1):265-9.

Sign-in to see more